Invention Grant
- Patent Title: Oncolytic virus for expression of immune checkpoint modulators
-
Application No.: US15325562Application Date: 2015-07-16
-
Publication No.: US10555981B2Publication Date: 2020-02-11
- Inventor: Nathalie Silvestre , Michel Geist , Karola Rittner , Jean-Baptiste Marchand , Christine Thioudellet
- Applicant: Transgene SA
- Applicant Address: unknown Illkirch Graffenstaden
- Assignee: Transgene S.A.
- Current Assignee: Transgene S.A.
- Current Assignee Address: unknown Illkirch Graffenstaden
- Agency: Buchanan Ingersoll & Rooney PC
- Priority: EP14306153 20140716
- International Application: PCT/EP2015/066263 WO 20150716
- International Announcement: WO2016/008976 WO 20160121
- Main IPC: A61K35/768
- IPC: A61K35/768 ; C07K16/28 ; A61K9/00 ; C07K14/535 ; C12N7/00 ; C12N9/10 ; C12N9/80 ; A61K39/00
Abstract:
The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.
Public/Granted literature
- US20170157188A1 ONCOLYTIC VIRUS FOR EXPRESSION OF IMMUNE CHECKPOINT MODULATORS Public/Granted day:2017-06-08
Information query
IPC分类:
